Agenus | AGEN - Operating Expenses


Agenus reported $-199.08M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celldex Therapeutics USD 714.56M 258.34M Jun/2026
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Incyte USD 973.64M 4.65B Jun/2026
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 18.93B 1.09B Sep/2026
Jiangsu Hengrui CNY 5.56B 39.12M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck EUR 4.34B 249M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Northwest Biotherapeutics USD 11.39M 120.04M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 126.36M 6.37M Jun/2026